Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Holding EXEL?
Track your performance easily
EXEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.02 - $36.97
Previous CloseN/A
Volume463.09K
Average Volume (3M)1.94M
Market Cap
$9.85B
Enterprise Value$6.57B
Total Cash (Recent Filing)$419.80M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)22.0
Beta0.41
Next Earnings
Feb 11, 2025EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding285,579,000
10 Day Avg. Volume1,517,165
30 Day Avg. Volume1,938,039
Standard Deviation0.11
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.69
Price to Cash Flow (P/CF)9.00
P/FCF Ratio9.30
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit3.74
Enterprise Value/Ebitda10.84
Forecast
1Y Price Target
$35.13Price Target Upside1.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Exelixis News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement raised 2024 total revenue guidance to $2.15-2.2B and net product revenue guidance to $1.775-1.825B, indicating strong financial growth prospects.
Market PositioningCabo continues to be the market leader in the RCC TKI space, with 42.4% TRx share, reinforcing its strong competitive position.
Product DevelopmentThe company is anticipated to grow unit sales of its products and add indications for Cabometyx, with an expectation of commercializing a product from its pipeline, showcasing robust product development potential.
Bears Say
Clinical Trial ConcernsNeither of the cabozantinib studies demonstrated a statistically significant benefit in overall survival.
Market UncertaintyThere is uncertainty regarding the ability of the company to replace and grow revenues through and beyond the 2030 cabozantinib patent cliff.
Regulatory ChallengesThe FDA is requiring an Oncologic Drugs Advisory Committee meeting to discuss the sNDA for cabozantinib in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic NET.
---
Ownership Overview
2.89% Insiders
24.52% Mutual Funds
0.05% Other Institutional Investors
45.85% Public Companies and Individual Investors
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $20.02 and its highest was $36.97 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $9.85B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Feb 11, 2025 which is in 33 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Oct 29, 2024. The company reported $0.4 earnings per share for the quarter, beating the consensus estimate of $0.339 by $0.061.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.39.
How many shares outstanding does Exelixis have?
Exelixis has 285,579,000 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.4 in its last earnings report, beating expectations of $0.339. Following the earnings report the stock price went up 12.913%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 659M.
---
Exelixis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.13 (1.83% Upside)
$35.13 (1.83% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 93%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.06%
12-Months-Change
Fundamentals
Return on Equity
20.52%
Trailing 12-Months
Asset Growth
-0.56%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EXEL Company Deck
---
EXEL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment, highlighted by significant revenue growth, strategic collaborations, and a strong market position. Despite some challenges related to operating expenses and market competition, the forward-looking prospects, including the successful ANDA ruling and the partnership with Merck, signal a robust outlook for the company.Read More>---
EXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
---
EXEL Stock 12 Month Forecast
Average Price Target
$35.13
▲(1.83% Upside)
Technical Analysis
Best Analysts Covering EXEL
1 Year
1 Year Success Rate
27/31 ratings generated profit
1 Year Average Return
+26.15%
reiterated a buy rating 2 months ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 87.10% of your transactions generating a profit, with an average return of +26.15% per trade.
---